Tissue-specific synthesis and oxidative metabolism of estrogens.

C. R. Jefcoate, J. G. Liehr, R. J. Santen, T. R. Sutter, J. D. Yager, W. Yue, S. J. Santner, Rajeshwar R Tekmal, L. Demers, R. Pauley, F. Naftolin, G. Mor, L. Berstein

Research output: Contribution to journalArticle

234 Citations (Scopus)

Abstract

Estrogen exposure represents the major known risk factor for development of breast cancer in women and is implicated in the development of prostate cancer in men. Human breast tissue has been shown to be a site of oxidative metabolism of estrogen due to the presence of specific cytochrome P450 enzymes. The oxidative metabolism of 17beta-estradiol (E2) to E2-3,4-quinone metabolites by an E2-4-hydroxylase in breast tissue provides a rational hypothesis to explain the mammary carcinogenic effects of estrogen in women because this metabolite is directly genotoxic and can undergo redox cycling to form genotoxic reactive oxygen species. In this chapter, evidence in support of this hypothesis and of the role of P4501B1 as the 4-hydroxylase expressed in human breast tissue is reviewed. However, the plausibility of this hypothesis has been questioned on the grounds that insufficient E2 is present in breast tissue to be converted to biologically significant amounts of metabolite. This critique is based on the assumption that plasma and tissue E2 levels are concordant. However, breast cancer tissue E2 levels are 10-fold to 50-fold higher in postmenopausal women than predicted from plasma levels. Consequently, factors must be present to alter breast tissue E2 levels independently of plasma concentrations. One such factor may be the local production of E2 in breast tissue through the enzyme aromatase, and the evidence supporting the expression of aromatase in breast tissue is also reviewed in this chapter. If correct, mutations or environmental factors enhancing aromatase activity might result in high tissue concentrations of E2 that would likely be sufficient to serve as substrates for CYP1B1, given its high affinity for E2. This concept, if verified experimentally, would provide plausibility to the hypothesis that sufficient E2 may be present in tissue for formation of catechol metabolites that are estrogenic and which, upon further oxidative metabolism, form genotoxic species at levels that may contribute to estrogen carcinogenesis.

Original languageEnglish (US)
Pages (from-to)95-112
Number of pages18
JournalJournal of the National Cancer Institute. Monographs
Issue number27
StatePublished - 2000
Externally publishedYes

Fingerprint

Estrogens
Breast
Aromatase
Mixed Function Oxygenases
Cytochrome P-450 Enzyme System
Breast Neoplasms
Oxidation-Reduction
Estradiol
Reactive Oxygen Species
Prostatic Neoplasms
Carcinogenesis
Mutation
Enzymes

Cite this

Jefcoate, C. R., Liehr, J. G., Santen, R. J., Sutter, T. R., Yager, J. D., Yue, W., ... Berstein, L. (2000). Tissue-specific synthesis and oxidative metabolism of estrogens. Journal of the National Cancer Institute. Monographs, (27), 95-112.

Tissue-specific synthesis and oxidative metabolism of estrogens. / Jefcoate, C. R.; Liehr, J. G.; Santen, R. J.; Sutter, T. R.; Yager, J. D.; Yue, W.; Santner, S. J.; Tekmal, Rajeshwar R; Demers, L.; Pauley, R.; Naftolin, F.; Mor, G.; Berstein, L.

In: Journal of the National Cancer Institute. Monographs, No. 27, 2000, p. 95-112.

Research output: Contribution to journalArticle

Jefcoate, CR, Liehr, JG, Santen, RJ, Sutter, TR, Yager, JD, Yue, W, Santner, SJ, Tekmal, RR, Demers, L, Pauley, R, Naftolin, F, Mor, G & Berstein, L 2000, 'Tissue-specific synthesis and oxidative metabolism of estrogens.', Journal of the National Cancer Institute. Monographs, no. 27, pp. 95-112.
Jefcoate CR, Liehr JG, Santen RJ, Sutter TR, Yager JD, Yue W et al. Tissue-specific synthesis and oxidative metabolism of estrogens. Journal of the National Cancer Institute. Monographs. 2000;(27):95-112.
Jefcoate, C. R. ; Liehr, J. G. ; Santen, R. J. ; Sutter, T. R. ; Yager, J. D. ; Yue, W. ; Santner, S. J. ; Tekmal, Rajeshwar R ; Demers, L. ; Pauley, R. ; Naftolin, F. ; Mor, G. ; Berstein, L. / Tissue-specific synthesis and oxidative metabolism of estrogens. In: Journal of the National Cancer Institute. Monographs. 2000 ; No. 27. pp. 95-112.
@article{dc04159807424e918e99de36c72a9a14,
title = "Tissue-specific synthesis and oxidative metabolism of estrogens.",
abstract = "Estrogen exposure represents the major known risk factor for development of breast cancer in women and is implicated in the development of prostate cancer in men. Human breast tissue has been shown to be a site of oxidative metabolism of estrogen due to the presence of specific cytochrome P450 enzymes. The oxidative metabolism of 17beta-estradiol (E2) to E2-3,4-quinone metabolites by an E2-4-hydroxylase in breast tissue provides a rational hypothesis to explain the mammary carcinogenic effects of estrogen in women because this metabolite is directly genotoxic and can undergo redox cycling to form genotoxic reactive oxygen species. In this chapter, evidence in support of this hypothesis and of the role of P4501B1 as the 4-hydroxylase expressed in human breast tissue is reviewed. However, the plausibility of this hypothesis has been questioned on the grounds that insufficient E2 is present in breast tissue to be converted to biologically significant amounts of metabolite. This critique is based on the assumption that plasma and tissue E2 levels are concordant. However, breast cancer tissue E2 levels are 10-fold to 50-fold higher in postmenopausal women than predicted from plasma levels. Consequently, factors must be present to alter breast tissue E2 levels independently of plasma concentrations. One such factor may be the local production of E2 in breast tissue through the enzyme aromatase, and the evidence supporting the expression of aromatase in breast tissue is also reviewed in this chapter. If correct, mutations or environmental factors enhancing aromatase activity might result in high tissue concentrations of E2 that would likely be sufficient to serve as substrates for CYP1B1, given its high affinity for E2. This concept, if verified experimentally, would provide plausibility to the hypothesis that sufficient E2 may be present in tissue for formation of catechol metabolites that are estrogenic and which, upon further oxidative metabolism, form genotoxic species at levels that may contribute to estrogen carcinogenesis.",
author = "Jefcoate, {C. R.} and Liehr, {J. G.} and Santen, {R. J.} and Sutter, {T. R.} and Yager, {J. D.} and W. Yue and Santner, {S. J.} and Tekmal, {Rajeshwar R} and L. Demers and R. Pauley and F. Naftolin and G. Mor and L. Berstein",
year = "2000",
language = "English (US)",
pages = "95--112",
journal = "NCI Monographs",
issn = "1052-6773",
publisher = "Oxford University Press",
number = "27",

}

TY - JOUR

T1 - Tissue-specific synthesis and oxidative metabolism of estrogens.

AU - Jefcoate, C. R.

AU - Liehr, J. G.

AU - Santen, R. J.

AU - Sutter, T. R.

AU - Yager, J. D.

AU - Yue, W.

AU - Santner, S. J.

AU - Tekmal, Rajeshwar R

AU - Demers, L.

AU - Pauley, R.

AU - Naftolin, F.

AU - Mor, G.

AU - Berstein, L.

PY - 2000

Y1 - 2000

N2 - Estrogen exposure represents the major known risk factor for development of breast cancer in women and is implicated in the development of prostate cancer in men. Human breast tissue has been shown to be a site of oxidative metabolism of estrogen due to the presence of specific cytochrome P450 enzymes. The oxidative metabolism of 17beta-estradiol (E2) to E2-3,4-quinone metabolites by an E2-4-hydroxylase in breast tissue provides a rational hypothesis to explain the mammary carcinogenic effects of estrogen in women because this metabolite is directly genotoxic and can undergo redox cycling to form genotoxic reactive oxygen species. In this chapter, evidence in support of this hypothesis and of the role of P4501B1 as the 4-hydroxylase expressed in human breast tissue is reviewed. However, the plausibility of this hypothesis has been questioned on the grounds that insufficient E2 is present in breast tissue to be converted to biologically significant amounts of metabolite. This critique is based on the assumption that plasma and tissue E2 levels are concordant. However, breast cancer tissue E2 levels are 10-fold to 50-fold higher in postmenopausal women than predicted from plasma levels. Consequently, factors must be present to alter breast tissue E2 levels independently of plasma concentrations. One such factor may be the local production of E2 in breast tissue through the enzyme aromatase, and the evidence supporting the expression of aromatase in breast tissue is also reviewed in this chapter. If correct, mutations or environmental factors enhancing aromatase activity might result in high tissue concentrations of E2 that would likely be sufficient to serve as substrates for CYP1B1, given its high affinity for E2. This concept, if verified experimentally, would provide plausibility to the hypothesis that sufficient E2 may be present in tissue for formation of catechol metabolites that are estrogenic and which, upon further oxidative metabolism, form genotoxic species at levels that may contribute to estrogen carcinogenesis.

AB - Estrogen exposure represents the major known risk factor for development of breast cancer in women and is implicated in the development of prostate cancer in men. Human breast tissue has been shown to be a site of oxidative metabolism of estrogen due to the presence of specific cytochrome P450 enzymes. The oxidative metabolism of 17beta-estradiol (E2) to E2-3,4-quinone metabolites by an E2-4-hydroxylase in breast tissue provides a rational hypothesis to explain the mammary carcinogenic effects of estrogen in women because this metabolite is directly genotoxic and can undergo redox cycling to form genotoxic reactive oxygen species. In this chapter, evidence in support of this hypothesis and of the role of P4501B1 as the 4-hydroxylase expressed in human breast tissue is reviewed. However, the plausibility of this hypothesis has been questioned on the grounds that insufficient E2 is present in breast tissue to be converted to biologically significant amounts of metabolite. This critique is based on the assumption that plasma and tissue E2 levels are concordant. However, breast cancer tissue E2 levels are 10-fold to 50-fold higher in postmenopausal women than predicted from plasma levels. Consequently, factors must be present to alter breast tissue E2 levels independently of plasma concentrations. One such factor may be the local production of E2 in breast tissue through the enzyme aromatase, and the evidence supporting the expression of aromatase in breast tissue is also reviewed in this chapter. If correct, mutations or environmental factors enhancing aromatase activity might result in high tissue concentrations of E2 that would likely be sufficient to serve as substrates for CYP1B1, given its high affinity for E2. This concept, if verified experimentally, would provide plausibility to the hypothesis that sufficient E2 may be present in tissue for formation of catechol metabolites that are estrogenic and which, upon further oxidative metabolism, form genotoxic species at levels that may contribute to estrogen carcinogenesis.

UR - http://www.scopus.com/inward/record.url?scp=0033657888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033657888&partnerID=8YFLogxK

M3 - Article

C2 - 10963622

AN - SCOPUS:0033657888

SP - 95

EP - 112

JO - NCI Monographs

JF - NCI Monographs

SN - 1052-6773

IS - 27

ER -